Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
935
Views
1
CrossRef citations to date
0
Altmetric
Influenza – Letter

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years

J. Kevin Yina Global Medical Affairs, Sanofi, Singapore;b Faculty of Medicine and Health, The University of Sydney, NSW, AustraliaCorrespondence[email protected]
View further author information
,
Stephanie Pepinc Global Clinical Sciences, Sanofi, Lyon, FranceView further author information
,
Robertus van Aalstd Department of Modeling, Epidemiology and Data Science, Global Medical Affairs, Sanofi, Lyon, France;e Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA;f Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsView further author information
,
Matthew M. Loiaconog Global Medical Evidence Generation, Sanofi, Swiftwater, PA, USAView further author information
&
Sandrine I. Samsonh Global Medical Affairs, Sanofi, Lyon, FranceView further author information
Article: 2106749 | Published online: 01 Aug 2022

References

  • Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine. 2021;39:1–3. doi:10.1016/j.vaccine.2020.09.004.
  • Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: A randomized Phase III trial. Hum Vaccin Immunother. 2021;17:5475–5486. doi:10.1080/21645515.2021.1983387.
  • Hadigal S, Colombo L, Haughie S. Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: A randomized Phase III trial”. Hum Vaccin Immunother. 2022:2085470. doi:10.1080/21645515.2022.2085470.
  • DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645. doi:10.1056/NEJMoa1315727.
  • The U.S. Centers for Disease Control and Prevention (CDC). Vaccine effectiveness: how well do flu vaccines work? 2021. https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm.
  • The U.S. Centers for Disease Control and Prevention (CDC). Seasonal Influenza Vaccine Effectiveness, 2011-2012. 2018. https://www.cdc.gov/flu/vaccines-work/2011-2012.html.
  • The U.S. Centers for Disease Control and Prevention (CDC). Seasonal Influenza Vaccine Effectiveness, 2012-2013. 2018. https://www.cdc.gov/flu/vaccines-work/2012-2013.html.
  • World Health Organization (WHO). Vaccines against influenza: WHO position paper. Wkly Epidemiol Rec 2022;19:185–208.
  • Wooten KG, Wortley PM, Singleton JA, Euler GL. Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and Hispanic Americans. Vaccine. 2012;30:6927–6934. doi:10.1016/j.vaccine.2012.08.036.
  • Australian Government Department of Health. Australian influenza surveillance Report No. 05; Reporting fortnight: 23 May to 05 June 2022. 2022.
  • Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdox1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFlucov): A multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277–2287. doi:10.1016/S0140-6736(21)02329-1.
  • Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: A phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392–402. doi:10.1016/S2213-2600(21)00557-9.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.